R01 CA164490/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2012	2
2013	1
2014	6
2015	1
2016	1
2017	2
2018	1
2019	1
2020	3
2024	0

1

Metabolic Imaging of Glutamine in Cancer.

Zhu L, Ploessl K, Zhou R, Mankoff D, Kung HF. Zhu L, et al. J Nucl Med. 2017 Apr;58(4):533-537. doi: 10.2967/jnumed.116.182345. Epub 2017 Feb 23. J Nucl Med. 2017. PMID: 28232608 Free PMC article. Review.

2

PET/SPECT imaging agents for neurodegenerative diseases.

Zhu L, Ploessl K, Kung HF. Zhu L, et al. Chem Soc Rev. 2014 Oct 7;43(19):6683-91. doi: 10.1039/c3cs60430f. Chem Soc Rev. 2014. PMID: 24676152 Free PMC article. Review.

3

The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology.

Dunphy MPS, Pillarsetty N. Dunphy MPS, et al. Cancers (Basel). 2020 Sep 22;12(9):2712. doi: 10.3390/cancers12092712. Cancers (Basel). 2020. PMID: 32971780 Free PMC article. Review.

4

Synthesis and evaluation of ¹⁸F labeled FET prodrugs for tumor imaging.

Wang L, Lieberman BP, Ploessl K, Kung HF. Wang L, et al. Nucl Med Biol. 2014 Jan;41(1):58-67. doi: 10.1016/j.nucmedbio.2013.09.011. Epub 2013 Oct 9. Nucl Med Biol. 2014. PMID: 24183614 Free PMC article.

5

Pharmacokinetic Assessment of ¹⁸F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer.

Grkovski M, Goel R, Krebs S, Staton KD, Harding JJ, Mellinghoff IK, Humm JL, Dunphy MPS. Grkovski M, et al. J Nucl Med. 2020 Mar;61(3):357-366. doi: 10.2967/jnumed.119.229740. Epub 2019 Oct 10. J Nucl Med. 2020. PMID: 31601700 Free PMC article. Clinical Trial.

6

Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate.

Cooper AJ, Krasnikov BF, Pinto JT, Kung HF, Li J, Ploessl K. Cooper AJ, et al. Comp Biochem Physiol B Biochem Mol Biol. 2012 Sep;163(1):108-20. doi: 10.1016/j.cbpb.2012.05.010. Epub 2012 May 19. Comp Biochem Physiol B Biochem Mol Biol. 2012. PMID: 22613816 Free PMC article.

7

First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.

Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico P, Weber WA, Lyashchenko SK, Lewis JS, Larson SM, Dunphy MPS. Krebs S, et al. J Nucl Med. 2020 Nov;61(11):1580-1587. doi: 10.2967/jnumed.119.234864. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169913 Free PMC article.

8

[(18)F](2S,4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent.

Wu Z, Zha Z, Li G, Lieberman BP, Choi SR, Ploessl K, Kung HF. Wu Z, et al. Mol Pharm. 2014 Nov 3;11(11):3852-66. doi: 10.1021/mp500236y. Epub 2014 Aug 11. Mol Pharm. 2014. PMID: 25095908 Free PMC article.

9

Synthesis and evaluation of 18F labeled alanine derivatives as potential tumor imaging agents.

Wang L, Zha Z, Qu W, Qiao H, Lieberman BP, Plössl K, Kung HF. Wang L, et al. Nucl Med Biol. 2012 Oct;39(7):933-43. doi: 10.1016/j.nucmedbio.2012.03.007. Epub 2012 Apr 26. Nucl Med Biol. 2012. PMID: 22542392 Free PMC article.

10

Oncogene pathway activation in mammary tumors dictates FDG-PET uptake.

Alvarez JV, Belka GK, Pan TC, Chen CC, Blankemeyer E, Alavi A, Karp JS, Chodosh LA. Alvarez JV, et al. Cancer Res. 2014 Dec 15;74(24):7583-98. doi: 10.1158/0008-5472.CAN-14-1235. Epub 2014 Sep 19. Cancer Res. 2014. PMID: 25239452 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year